Taysha Gene Therapies, Inc. Quarterly Return On Equity in % from Q3 2020 to Q3 2024

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Taysha Gene Therapies, Inc. quarterly/annual Return On Equity history and growth rate from Q3 2020 to Q3 2024.
  • Taysha Gene Therapies, Inc. Return On Equity for the quarter ending September 30, 2024 was -27.9 %, a 103% decline year-over-year.
  • Taysha Gene Therapies, Inc. annual Return On Equity for 2023 was 1.7K %.
  • Taysha Gene Therapies, Inc. annual Return On Equity for 2022 was -700 %, a 547% decline from 2021.
  • Taysha Gene Therapies, Inc. annual Return On Equity for 2021 was -108 %, a 119% decline from 2020.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q3 2024 -27.9 -884 -103% Jul 1, 2024 Sep 30, 2024
Q2 2024 -243 -1.47K -120% Apr 1, 2024 Jun 30, 2024
Q1 2024 -1.11K +716 +39.2% Jan 1, 2024 Mar 31, 2024
Q4 2023 1.7K +2.4K Oct 1, 2023 Dec 31, 2023
Q3 2023 856 +1.2K Jul 1, 2023 Sep 30, 2023
Q2 2023 1.23K +1.46K Apr 1, 2023 Jun 30, 2023
Q1 2023 -1.83K -1.66K -1020% Jan 1, 2023 Mar 31, 2023
Q4 2022 -700 -592 -547% Oct 1, 2022 Dec 31, 2022
Q3 2022 -341 -270 -379% Jul 1, 2022 Sep 30, 2022
Q2 2022 -233 -187 -409% Apr 1, 2022 Jun 30, 2022
Q1 2022 -163 -115 -237% Jan 1, 2022 Mar 31, 2022
Q4 2021 -108 -58.9 -119% Oct 1, 2021 Dec 31, 2021
Q3 2021 -71.1 +1.68 +2.31% Jul 1, 2021 Sep 30, 2021
Q2 2021 -45.8 Apr 1, 2021 Jun 30, 2021
Q1 2021 -48.5 Jan 1, 2021 Mar 31, 2021
Q4 2020 -49.3 Oct 1, 2020 Dec 31, 2020
Q3 2020 -72.8 Jul 1, 2020 Sep 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.